Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs PFE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PFE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

PFE Overall Winner 6-Pillar Tally: MRNA 1 – 5 PFE Matrix Metrics: MRNA 3 – 7 PFE

As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas PFE carries 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin).

  • Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs PFE
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
PFE NYSE Head-to-Head Winner
Pfizer Inc.
Pharmaceutical Preparations
$27.40
-0.51% 1D
Market Cap $157.0B
TTM Revenue $63.6B
Forward P/E 9.3x
Beta / 30D Vol 0.18β · 22% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 32.5 · SMA20: $29.32 · SMA50: $28.82

6-Pillar Scorecard Institutional Category Breakdown (MRNA 1 – 5 PFE)

Columns: Metric · MRNA · PFE
1. Valuation Multiples PFE
Forward P/E 23.0x 9.3x
Trailing P/E 23.0x 39.3x
PEG Ratio N/M 8.56x
EV / Revenue 33.1x 3.4x
2. Growth & Scale PFE
Revenue Growth (YoY) +29.2% -0.4%
Earnings Growth (YoY) -85.1% -9.7%
TTM Revenue (USD) $2.52B $63.6B
Market Cap $80.7B $157.0B
3. Profitability & Quality PFE
Gross Margin -42.0% 74.9%
Operating Margin -80.8% 29.1%
Net Profit Margin -110.5% 6.3%
Return on Equity (ROE) -34.5% 4.5%
4. Balance Sheet & Cash Flow PFE
Cash Generation (TTM) -$2.04B $11.8B
Cash Flow Margin -81.0% 18.5%
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $60.8B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) 7.66%
5. Options & Positioning PFE
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 89.6% (52nd %ile) 48.1% (58th %ile)
Put/Call OI Skew 1.05x (Balanced) 0.62x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 45.8% of Rev ($29.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (3) vs PFE (7)
Institutional Metric MRNA PFE Criterion Row Edge
Market Capitalization
Scale
$80.7B $157.0B Larger Scale PFE
Trailing P/E Ratio
Valuation
23.0x 39.3x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 9.3x Lower Multiple PFE
Revenue Growth (YoY)
Growth
+29.2% -0.4% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 29.1% Higher Margin PFE
Net Profit Margin
Profitability
-110.5% 6.3% Higher Margin PFE
Return on Equity (ROE)
Capital Efficiency
-34.5% 4.5% Higher ROE PFE
52-Week Range Position
Momentum
67% ($22–$281) 48% ($24–$31) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.18β · 22% Vol Lower Realized Risk PFE
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite PFE
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $63.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 74.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 8.56x PEG · 3.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $11.8B ($60.8B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +6.16 pp
MRNA: -3.77% · PFE: -9.93%
3M Horizon MRNA +42.44 pp
MRNA: +40.4% · PFE: -2.04%
6M Horizon MRNA +310.17 pp
MRNA: +315.96% · PFE: +5.79%
1Y Horizon MRNA +696.32 pp
MRNA: +706.45% · PFE: +10.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue PFE Revenue MRNA Op. Margin PFE Op. Margin Margin Leader
FY2018 $140M $40.8B -306.0% 27.3% PFE
FY2019 $60M $40.9B -906.8% 39.2% PFE
FY2020 $800M $41.6B -95.0% 22.0% PFE
FY2021 $18.5B $73.6B 72.0% 29.8% MRNA
FY2022 $19.3B $91.8B 48.9% 34.2% MRNA
FY2023 $6.85B $50.9B -61.9% 4.2% PFE
FY2024 $3.24B $63.6B -121.9% 12.6% PFE
FY2025 $1.94B $62.6B -158.1% 12.4% PFE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PFE CONSOLIDATION
56d in phase · OBV DISTRIBUTION
Current IV 48.1%
IV Percentile 58th %ile
Put/Call OI Skew 0.62x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PFE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. PFE: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. PFE ($2,886) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
PFE Spot $28.86 · IV 25.6%
PFE Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $29 / $30 Bull Call Spread

Buy 2x $29C · Sell 2x $30C · 31d

Net Entry $84 Debit
T+5d @ +5% Move +$52 (+62%)
Max Risk / Buffer $84 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $27 / $25 Bull Put Spread

Sell 2x $27P · Buy 2x $25P · 59d

Net Entry $58 Credit
Max Credit / Yield +$58 (+17.0% RoM)
Max Risk / Buffer -7.4% Cushion ($342 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
PFE Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $157.0B market capitalization and 29.1% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($29.1B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs PFE Key Questions & Quantitative Answers

As of Nov 20, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas PFE carries 49.4/100 (HOLD) at $27.40 (9.3x Forward P/E, 29.1% operating margin). Growth vs. Quality Trade-Off: PFE earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.18β · 22% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

PFE leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with PFE at -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while PFE shifted +53.3%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($29.1B) (0 disclosures) for PFE.

PFE screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas PFE trades at 9.3x Forward P/E, 39.3x Trailing P/E, 8.56x PEG, and 3.4x EV/Revenue (18.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus PFE (4.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, PFE carries 48.1% implied volatility (58th %ile, Balanced (25th–60th %ile)), a 0.62x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.18β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.